

# 3H Medi Solution Global Capabilities



## Oncology Department

some pretty spectacular statistics..

100 KOLs

20,000 Patients

50+ Research



80+ Trials 1 Million Accesses

150 Events



# KOL (Key Opinion Leader) agreeing with Oncolo Team



 $\mathbf{100} +_{\mathsf{KOLs}}$ 

Over 100 cancer specialists support Many professors/deans

#### **Oncolo Medical Supporter**


A medical representative who agreed to cooperate with 3H Oncolo information site.






### E-mail members

## **1Million** Users Visit ONCOLO® per Month.





Lung Cancer	21.5%	Cervical Cancer	1.4%
<b>Breast Cancer</b>	17.8%	Neuroendocrine Tumor	1.2%
<b>Colorectal Cancer</b>	7.9%	Thyroid Cancer	1.2%
Stomach Cancer	7.0%	Brain Tumor	1.2%
Ovarian Cancer	4.5%	Malignant Mesothelioma	1.2%
Pancreatic Cancer	3.7%	Melanoma	0.6%
<b>Prostate Cancer</b>	2.7%	Laryngeal Cancer	0.4%
Kidney Cancer	2.7%	Malignant Lymphoma	2.5%
<b>Uterine Body Cancer</b>	2.3%	Leukemia	2.1%
Liver Cancer	2.1%	Multiple Myeloma	1.2%
Canteen Cancers	2.1%	Other	11.2%
Bladder Cancer	1.6%		

Our website is visited not only by patients, but also by many pharmaceutical/medical related staffs



#### Clinical Trial Advertising (Mar 2016~Till Now)



Triple-negative breast cancer



Muscle layer non-invasive bladder cancer



Head and neck squamous cell carcinoma



Rare cancer (basket)



Muscle-invasive bladder cancer



Esophageal cancer



Small-cell lung cancer



BRCA breast cancer




Low-grade Non-Hodgkin lymphoma



**GIST** 



Non-metastatic castration-resistant prostate cancer



Malignant pleural mesothelioma

Achievement (include plans): More than 80 trials: Brain tumor: 2. Head and neck cancer: 1. Salivary gland cancer: 1. Non-small cell lung cancer: 9. Small-cell lung cancer: 3. Breast cancer: 5. Malignant pleural mesothelioma: 5. Esophageal cancer: 2. Gastric cancer: 2. Hepatocellular carcinoma: 1. Renal cell carcinoma: 2. Bladder cancer: 3. Colorectal cancer: 1. GIST: 1. Prostate cancer: 1. Malignant lymphoma: 6. Leukemia: 7. Multiple myeloma: 1. Rare cancer basket study: 1. Melanoma: 2. Unknown primary cancer: 1. Solid cancer: 1. Bone metastasis sarcoma: 1. uterine carcinosarcoma: 1. Small intestine adenocarcinoma: 1. Glioma: 1

- · Ads for hematologic cancer are increasing and has a very high responsive rate
- · Ads for immune checkpoint inhibitor is decreasing but has a high responsive rate
- · Connections with sites go up and medical investigator trials are increasing as well

#### Incurable diseases · Rare disease information site RareS.



- ◆Rare disease information site RareS.
- ◆URL: https://raresnet.com/
- ♦since: 2018 Feb~
- ◆ Relation: NPO incurable disease network
- ◆page views : 20,000/month
- ♦ active users : 1,000/month
- ◆ Patient Organization: 109

- latest news : Collect and publish news related to rare diseases
- various types of rare diseases : designated rare diseases + rare cancers, pediatric chronic specific diseases
- clinical trial information: posting information about studies which are recruiting participants.
- event information: information on national events held by various organizations.
- Incurable disease medical liaison council · Posting information on updates of these organizations



**Study Details:** Siteless Virtual Study of Adverse Event Monitoring Applications in Cancer Patients site less Virtual Study for Validation of Adverse Events Monitoring Application in Oncology

Indication: Projected number of subjects with advanced cancer

Patients: 100 subjects

**ONCOLOGY** 


**Study Period:** November 2019 to March 2020

Objectives: P-Guardian Systems Validation and Exploration of Changes in Patients' Quality of Life

**Scheduled scale:** PRO-CTCAE(Weekly), FACT-G(Monthly)

Sensor-Acquisition Scale: Activity (Calorie, METs), SpO2, Heart Rate, Sleeps

## Patient Insight // Cancer treatment patients



#### Expert Analysis //

- ✓ There are patients who can not consult their doctor about their pain and anxiety.
- Patients usually get the care/treatment after consultation but there are the cases where care/treatment was not provided as well as even after receiving there was not improvement some said. So it is necessary to improve the current situation.
- ✓ After consultation 80% of patients were satisfied however solving the pain & anxiety was key points
- ✓ By communicating to doctor about their pain and anxiety to and getting the appropriate care which resulted in acceptance of longer duration of cancer treatment.

#### **Project Summary //**

Sponsor	Global Pharma	
Support from 3H	Quantitative Research	
Timing of consultation	Considering Disease Awareness	
Target	Ongoing treatment Cancer Patients	
# of sample	n=287(BC,LC,CML,RCC)	
Target area	All Japan	
Medias used	Oncolo	

#### Impressive Number //

Japanese Cancer Patients were interviewed to know about their pain and their care giving condition whether it is sufficient or not.

Those who felt uneasy even once was 89.9%, where most of them had an anxiety experience. In addition, 65.5% answered that they felt pain even once, and those who had pain during cancer treatments were over 60%.

There were more than half of patients who answered that "pain" and "anxiety" were affecting their cancer treatment. Further, half of total patient answered that they have consulted their doctors about pain where only 20% of patients replied that they have consulted to their doctors for anxiety. However 41.7% replied that they had not got care after consulted with doctor about their anxiety.

Copyright © 3H





# Thank you

To know more please contact: imran@3h-ms.co.jp